Australia, June 5 -- Definium Therapeutics US Inc., owns the trademark (2632729) for 'DEFINIUM' till Feb. 3, 2036.
Status: protected:
Registered/protected
Classes: 5 [Pharmaceuticals; pharmaceutical preparations; pharmaceuticals for the treatment of mental health conditions; pharmaceutical preparations for the treatment of mental health conditions; pharmaceutical preparations, namely, psychotropic, psychoactive, and psychedelic medicinal preparations for the treatment of mental health conditions; pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, anxiety, depression, post-traumatic stress disorder, and mood disorders; pharmaceutical preparations for the treatment of substance-use and addictive disorders.] and 42 [Drug discovery services; pharmaceutical drug development services; pharmaceutical research and development; pharmaceutical research services; providing medical and scientific research information in the fields of pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the fields of psychiatry, neurology, and addiction medicine; medical and scientific research, namely, conducting clinical trials for others in the field of psychedelic-based therapeutics.]
Type of Mark: Word
Date of Acceptance: March 27
Registration Advertised: June 4
For further details contact John Paul Oleksiuk Cooley LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2632729.
Disclaimer: Curated by HT Syndication.
